JAZZ Positive Sentiment
Jazz Pharmaceuticals to Participate in Upcoming Investor EventsUSA - EnglishUSA - English
Wednesday, December 17, 2025 BiopharmaWatch Research 1 min read Key Takeaway: Jazz Pharmaceuticals has announced its participation in two upcoming investor events: the Zanidatamab HERIZON-GEA-01 Investor Webcast on January 9, 2026, and the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. Audio webcasts of these presentations will be available on the company's website for 30 days following the events. Jazz Pharmaceuticals continues to focus on developing innovative therapies for serious diseases.
Full Press Release Details
DUBLIN,Dec. 17, 2025/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq:JAZZ) today announced that the Company will participate in the following investor events:
Zanidatamab HERIZON-GEA-01 Investor Webcast on Friday, January 9, 2026
44thAnnual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026
Audio webcasts of the presentations may be accessed via the Investors section of the Jazz Pharmaceuticals website at
https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be available on the website for 30 days.
About Jazz PharmaceuticalsJazz Pharmaceuticals plc (Nasdaq:JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing potentially life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visitwww.jazzpharmaceuticals.comfor more information.
Investors:Jack SpinksExecutive Director, Investor RelationsJazz Pharmaceuticals plc[email protected]Ireland, +353 1 634 3211U.S., +1 650 496 2717
Media:Kristin BhavnaniHead of Global Corporate CommunicationsJazz Pharmaceuticals plc[email protected]Ireland, +353 1 637 2141U.S., +1 215 867 4948